NO923130L - Behandling av kongestiv hjertesvikt - Google Patents

Behandling av kongestiv hjertesvikt

Info

Publication number
NO923130L
NO923130L NO92923130A NO923130A NO923130L NO 923130 L NO923130 L NO 923130L NO 92923130 A NO92923130 A NO 92923130A NO 923130 A NO923130 A NO 923130A NO 923130 L NO923130 L NO 923130L
Authority
NO
Norway
Prior art keywords
heart failure
congestive heart
treatment
converting enzyme
angiotensin converting
Prior art date
Application number
NO92923130A
Other languages
English (en)
Norwegian (no)
Other versions
NO923130D0 (no
Inventor
Andrea Ann Seymour
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of NO923130D0 publication Critical patent/NO923130D0/no
Publication of NO923130L publication Critical patent/NO923130L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO92923130A 1991-08-12 1992-08-11 Behandling av kongestiv hjertesvikt NO923130L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/744,208 US5225401A (en) 1991-08-12 1991-08-12 Treatment of congestive heart failure

Publications (2)

Publication Number Publication Date
NO923130D0 NO923130D0 (no) 1992-08-11
NO923130L true NO923130L (no) 1993-02-15

Family

ID=24991881

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92923130A NO923130L (no) 1991-08-12 1992-08-11 Behandling av kongestiv hjertesvikt

Country Status (13)

Country Link
US (1) US5225401A (ja)
EP (1) EP0527624A3 (ja)
JP (1) JPH05194272A (ja)
KR (1) KR100241678B1 (ja)
AU (1) AU655649B2 (ja)
CA (1) CA2075671A1 (ja)
HU (1) HUT65691A (ja)
IL (1) IL102571A (ja)
MX (1) MX9204625A (ja)
NO (1) NO923130L (ja)
NZ (1) NZ243623A (ja)
RU (1) RU2080112C1 (ja)
ZA (1) ZA925698B (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
US5654294A (en) * 1993-05-13 1997-08-05 Bristol-Myers Squibb Spiro lactam dual action inhibitors
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
IT1277736B1 (it) * 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
US5849681A (en) * 1996-02-09 1998-12-15 S. C. Johnson & Son, Inc. Glass cleaner with enhanced anti-streaking properties
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
KR20020040795A (ko) * 1999-08-30 2002-05-30 로버트 흐라이탁, 미쉘 베스트 심혈관 사고 예방용 레닌-안지오텐신 시스템 억제제의 용도
CA2330904C (en) * 2001-01-11 2006-10-24 Bernard Charles Sherman Fosinopril sodium tablet formulation
AU2002348276A1 (en) * 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN101432025B (zh) * 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
EP2035450A2 (en) 2006-05-26 2009-03-18 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
JP2010508358A (ja) 2006-11-01 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8598314B2 (en) * 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
EP4259189A4 (en) * 2020-12-10 2024-02-28 BaroPace, Inc. TREATMENT OF DRUG-RESISTANT HYPERTENSION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION BY COMBINED TREATMENT WITH STIMULATION OF BARORECEPTORS AND BETA-BLOCKERS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88621I2 (fr) * 1980-10-23 1995-09-01 Schering Corp Sandopril
US4906615A (en) * 1980-12-18 1990-03-06 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4722810A (en) * 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4826816A (en) * 1984-09-24 1989-05-02 Schering Corporation Antihypertensive compounds
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4801609B1 (en) * 1987-03-27 1993-11-09 Mercapto-acylamino acid antihypertensives
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
EP0361365A1 (en) * 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
EP0495822A1 (en) * 1989-10-13 1992-07-29 Schering Corporation Carboxyalkyl dipeptide inhibitors of endopeptidases
US5389610A (en) * 1989-11-21 1995-02-14 Schering Corporation Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
WO1991009840A1 (en) * 1989-12-22 1991-07-11 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors

Also Published As

Publication number Publication date
AU2093392A (en) 1993-02-18
NO923130D0 (no) 1992-08-11
HUT65691A (en) 1994-07-28
IL102571A (en) 1997-07-13
IL102571A0 (en) 1993-01-14
KR100241678B1 (ko) 2000-03-02
EP0527624A2 (en) 1993-02-17
ZA925698B (en) 1993-03-02
NZ243623A (en) 1994-04-27
RU2080112C1 (ru) 1997-05-27
JPH05194272A (ja) 1993-08-03
HU9202616D0 (en) 1992-10-28
AU655649B2 (en) 1995-01-05
MX9204625A (es) 1993-04-01
KR930003912A (ko) 1993-03-22
EP0527624A3 (en) 1993-09-15
CA2075671A1 (en) 1993-02-13
US5225401A (en) 1993-07-06

Similar Documents

Publication Publication Date Title
NO923130L (no) Behandling av kongestiv hjertesvikt
BG97068A (bg) Фармацевтичен състав и метод за постигане на терапевтичен ефект
NZ309523A (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders
SE9103612D0 (sv) New peptide derivatives
MY111370A (en) Dual action inhibitors
MX9706069A (es) Nuevos inhibidores de la trombina.
RU92016534A (ru) Синергетические терапевтические композиции и способы достижения синергетического терапевтического эффекта
AP9200410A0 (en) Retroviral protease inhibitors.
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
TR199900389T2 (xx) �kame edilmi� 6,5-hetero-bisiklik t�revleri.
MY116947A (en) Protease inhibitors
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
DK0728144T3 (da) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteinaser
NO983688L (no) Serin-protease-inhibitorer
DE69402173D1 (de) Hemmung von Thrombin
IE840301L (en) Benzazocinone and benzazoninone derivatives
NO996578L (no) Urokinase-inhibitorer
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
NZ507835A (en) Heterocyclic derivatives which inhibit factor XA
NO983992L (no) Serinprotease inhibitorer
ZA874123B (en) Variants of alpha1-antitrypsin which are useful,in particular,as kallikrein inhibitors
MX9801190A (es) Inhibidores de prolil endopeptidasa.
ATE261988T1 (de) Peptidomimetische inhibitoren von der protease des menschlichen cytomegalovirus